Bijwerkingencentrum Lareb

The Netherlands Pharmacovigilance Centre Lareb identifies risks associated with the use of medicines in daily practice and is the knowledge centre for adverse drugs reactions (ADRs). Analysis of reports lead to signals about adverse drug reactions. These signals are reported to and reviewed by the Dutch Medicines Evaluation Board (MEB). This intensive cooperation supports the MEB in its decisions with regard to its role in pharmacovigilance in the Netherlands and Europe. The Teratology Information Service (TIS) of Lareb is the knowledge centre on safety of drugs used before and during pregnancy and during lactation. The Dutch Pregnancy Drug Register (Moeders...

Meldcentrum,kenniscentrum,bijwerkingen,geneesmiddelen,vaccins,geneesmiddelenveiligheid,vaccinveiligheid,meldingen,onderzoek,lareb intensive monitoring,moeders van morgen,geneesmiddelengebruik zwangerschap,and geneesmiddelengebruik borstvoeding

Bijwerkingencentrum lareb operates in the Research services industry.

Bijwerkingencentrum lareb's revenue is 11m - 100m

Bijwerkingencentrum lareb has 51 - 200 employees.